Xconomy | Boston - Business + Technology in the Exponential Economy

Life Sciences, deals, Antibodies

Alexion Settles Legal Dispute

Ryan McBride 1/5/09

Alexion Pharmaceuticals (NASDAQ:ALXN) reports it will pay $25 million to PDL BioPharma (NASDAQ:PDLI) to license a patent related to humanizing antibodies and to settle a legal dispute between the two companies. Cheshire, CT-based Alexion says the license enables the firm to commercialize its humanized antibody eculizumab (Soliris)—now approved to treat a rare blood disorder called paroxysmal nocturnal hemoglobinuria in the U.S. and Europe—for any use without threat of legal action by PDL BioPharma.

Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com.


Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009 Xconomy. All rights reserved. Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.